Pfizer COVID Vaccine: Common and Rare Side Effects

Most people who receive the Pfizer-BioNTech COVID-19 vaccine experience mild, short-lived side effects that resolve within a day or two. Injection-site pain, fatigue, headache, muscle aches, and fever top the list, and they tend to be more pronounced after the second dose. Rare but more serious reactions, including myocarditis and anaphylaxis, have been documented through large-scale surveillance, and the risk profiles for these differ sharply by age and sex. Understanding what is common, what is rare, and what actually warrants concern is more useful than a simple list of possibilities.

What to Expect After Each Dose

The side-effect pattern shifts between doses. After the first shot, burning or pain at the injection site and fever are the most frequently reported reactions. In a study of 1,000 Pfizer recipients in Pakistan, about 70% reported injection-site burning and a similar proportion reported fever following dose one.¹ After the second dose, systemic symptoms ramp up. Muscle pain became the most commonly reported side effect in that same cohort, affecting about 63% of participants.¹ This escalation between doses is consistent across studies and reflects a more vigorous immune response the second time around, since the body has already been primed to recognize the spike protein.

In Pfizer’s own phase 2/3 trial data evaluated alongside other analyses, younger recipients were more likely to experience side effects and more likely to reach for pain medication afterward, though this did not affect the vaccine’s effectiveness.² Most common reactions, whether local soreness or a day of feeling run down, peak within 24 to 48 hours and clear on their own.

Who Tends to React More

Two factors shape the likelihood and intensity of side effects more than anything else: sex and age. In a study tracking booster-dose reactions, women reported roughly twice as many side effects as men (a median of six symptoms versus three), and they took longer to recover, with about 85% returning to normal compared to 94% of men over the follow-up period.³ Younger adults also reported more symptoms than older adults: a median of six in people under 65, compared to two in those 65 and older.³

A systematic review specifically examining gender differences with the Pfizer vaccine confirmed the pattern: the risk of both local and systemic side effects was consistently higher in females at all ages, after both doses. That included not only the expected pain at the injection site and fever but also sensory symptoms like tingling in the hands and face.⁴ The reasons likely involve hormonal differences in immune regulation. Estrogen amplifies certain arms of the immune response, which may drive both stronger protection and more noticeable side effects.

How Much of It Is the Nocebo Effect

A surprisingly large share of what people experience after vaccination may not be caused by the vaccine at all. In clinical trials, participants who received a placebo injection (saline, no vaccine) still reported headaches, fatigue, and body aches at high rates. A meta-analysis of placebo arms across COVID-19 vaccine trials found that these nocebo responses, as they are called, likely stem from anxiety, expectations, and the natural tendency to attribute any background symptom to the injection you just received.⁵

This is not to say that real vaccine-driven side effects do not exist. They do. But a meaningful chunk of the symptoms people report appears to have a psychological component. One study found that pre-existing vaccine hesitancy predicted how many side effects a person would report after a booster, even after controlling for other factors. The effect was particularly strong in men, where hesitancy accounted for a notable portion of the reported symptoms.⁶ If you go in expecting to feel terrible, you are more likely to interpret normal aches and tiredness as vaccine reactions.

Myocarditis and Pericarditis

The rare side effect that attracted the most scrutiny was myocarditis, an inflammation of the heart muscle. The risk concentrates sharply in one demographic: young males, particularly after the second dose. A systematic review reported incidence rates ranging from roughly 8 to 39 cases per 100,000 persons (or doses) in young males aged 12 to 24 after their second mRNA vaccine dose, depending on the study.⁷ Outside that narrow group, the risk drops off substantially.

The picture gets more complicated when you compare vaccine-related myocarditis to infection-related myocarditis. A large English study found that in men under 40, the number of excess myocarditis cases per million was higher after a second dose of the Moderna vaccine than after a positive COVID test, but for the Pfizer vaccine the excess risk was lower.⁸ This distinction between the two mRNA vaccines matters: the Pfizer shot consistently appears to carry a lower myocarditis risk than Moderna, likely because it uses a smaller mRNA dose.

The mechanisms behind vaccine-associated myocarditis are still not fully nailed down. Proposed explanations include molecular mimicry, where the immune system confuses heart tissue for a viral target, and a dysregulated innate immune response.⁹ More recent work points to the lipid nanoparticles that carry the mRNA, suggesting they may trigger inflammatory pathways through pattern-recognition receptors, releasing pro-inflammatory signals that, in susceptible individuals, could contribute to heart inflammation.¹⁰ Most cases have been mild, presenting with chest pain and elevated cardiac markers that resolve within days to weeks. Serious outcomes have been very uncommon.

Anaphylaxis and Allergic Reactions

Anaphylaxis after the Pfizer vaccine is extremely rare, occurring in roughly 2 to 5 cases per million doses based on early surveillance data. When it does occur, onset is fast, typically within 15 minutes of the shot, which is why vaccination sites enforce a waiting period. Case investigations have identified polyethylene glycol (PEG), a stabilizer in the vaccine’s lipid nanoparticle shell, as a likely trigger. In documented cases, patients showed strong positive skin-prick test and immune-cell activation responses to PEG 2000, and one patient had detectable anti-PEG antibodies. Both patients tolerated a PEG-free vaccine afterward without incident.¹¹

PEG is used in countless pharmaceutical and consumer products, so most people tolerate it without issue. Those with a known history of anaphylaxis to PEG-containing products should flag this before vaccination. For everyone else, the 15-minute observation window at vaccination sites exists precisely to catch and treat the rare reaction quickly with epinephrine.

Swollen Lymph Nodes

Armpit swelling on the same side as the injection is more common than many people realize and can cause unnecessary alarm, especially in anyone who is overdue for a mammogram or has a history of cancer. An MRI study found that 65% of vaccinated participants showed axillary lymph node enlargement within two weeks of their shot.¹² The swelling can appear on the same side as the injection after either dose and can show up on ultrasound as enlarged, darkened nodes with increased blood flow.¹³

The practical concern is that vaccine-related lymph node swelling can mimic the imaging appearance of metastatic disease. Radiologists have updated guidelines to ask about recent vaccination before interpreting imaging. Reassuringly, the swelling resolves on its own. A follow-up study found that lymphadenopathy after Pfizer vaccination resolved faster than after Moderna vaccination, with the average time to resolution being about four months after the first dose.¹⁴ If you have imaging scheduled shortly after vaccination, mention the timing to your radiologist so they can interpret results in context.

Bell’s Palsy

Bell’s palsy, a sudden temporary weakness of the muscles on one side of the face, drew early attention as a potential vaccine side effect after a handful of cases appeared during the original clinical trials. Across published case reports, the onset has been variable, occurring anywhere from one day to nearly seven weeks after vaccination, with the average interval around 10 days. Among reported cases, left-side paralysis was more common than right-side, and most occurred after the Pfizer vaccine, though that partly reflects its dominant global market share.¹⁵

The more important question, though, is whether the vaccine actually causes Bell’s palsy at rates above what would occur by coincidence. A large meta-analysis comparing nearly 23 million Pfizer first-dose recipients to the same number of AstraZeneca recipients found no significant difference in Bell’s palsy rates between the two vaccines.¹⁶ Bell’s palsy has a baseline occurrence rate in the general population, and the evidence so far suggests that vaccination does not meaningfully push it higher.

Menstrual Cycle Changes

Menstrual irregularities were among the side effects that initially went underreported in clinical trials, partly because menstrual health was not tracked as an endpoint. Survey-based research has since confirmed that changes are not uncommon. In one cross-sectional study, about 55% of respondents reported some change in their menstrual cycle after vaccination, with cycle length being the most frequent change, followed by the number of bleeding days and flow volume.¹⁷ Intermenstrual bleeding (spotting between periods) was more frequently reported after a third Pfizer dose compared to Moderna.¹⁷

The disruptions generally appear to be temporary, lasting one to two cycles before returning to baseline. The likely explanation is that the systemic inflammatory response triggered by vaccination temporarily affects the hypothalamic-pituitary-ovarian axis, which regulates the cycle. Active safety monitoring in the UK identified menstrual disorders as a genuine safety signal, though reporting appeared to be amplified by media coverage of the topic, making it difficult to separate true incidence from heightened awareness.¹⁸ The changes do not appear to affect long-term fertility.

Safety During Pregnancy

Pregnant individuals were excluded from the original clinical trials, so early safety data came from registry studies and passive surveillance. The most comprehensive evidence is now reassuring. A systematic review covering more than 450,000 pregnant women who received the Pfizer vaccine found no increased risk of miscarriage, congenital anomalies, preterm birth, low birth weight, or neonatal death.¹⁹ These findings were consistent across trimesters and dose numbers.

Early data from the CDC’s v-safe pregnancy registry told a similar story: among nearly 3,960 enrolled participants with completed pregnancies, adverse outcomes occurred at rates comparable to pre-pandemic baseline populations. Injection-site pain was slightly more common in pregnant recipients than in nonpregnant women, while systemic symptoms like headache and fever were actually less frequent.²⁰ A large retrospective cohort study found that vaccinated individuals had significantly lower rates of stillbirth compared to unvaccinated individuals.²¹ This likely reflects both the vaccine’s protective effect against severe COVID during pregnancy and healthy-user patterns in observational data, but it underscores that vaccination during pregnancy has not been linked to harm.

Children and People With Immune Conditions

In children aged 5 to 11, the safety profile mirrors what is seen in adults but at lower intensity. An Italian real-world study found that about 69% of children reported some side effect, mostly local (injection-site pain or redness). Systemic reactions like fever were more common after the second dose, consistent with the adult pattern, but serious events were not observed.²²

For immunocompromised individuals, a reasonable worry is that a weakened immune system might either react differently to the vaccine or fail to mount a protective response. An open-label study of immunocompromised participants aged 2 and older found that local reactions were uniformly mild to moderate, with no severe or grade-4 local reactions. Injection-site pain and fatigue were the most common complaints, and their frequency tracked closely with age groups rather than immune status.²³ A separate study specifically looking at children aged 4 to 11 with autoimmune inflammatory rheumatic diseases found that adverse-event rates were similar between the autoimmune group and healthy controls, and disease activity remained stable after vaccination.²⁴ The main concern in this population is not extra side effects but rather a blunted immune response, which is why additional doses are recommended.

Getting the Flu Shot at the Same Time

If you have ever wondered whether rolling up both sleeves in the same visit is a bad idea, the evidence says it is not. A systematic review of studies examining co-administration of the Pfizer vaccine with seasonal influenza vaccines found that the incidence of both local and systemic side effects was comparable whether the two shots were given together or separately.²⁵ A randomized trial confirmed that simultaneous administration was noninferior to sequential dosing in terms of side-effect burden, with about a quarter of simultaneous recipients experiencing a composite reactogenicity outcome in the week after the visit compared to about 31% of those who spaced the vaccines out.²⁶ VAERS surveillance data showed no new or unexpected safety concerns when both vaccines were given at the same appointment.²⁷

Managing Post-Vaccination Symptoms

Over-the-counter pain relievers are the standard approach for post-vaccination aches and fever, and the data suggests they do not interfere with how well the vaccine works. In the Pfizer phase 2/3 trial, about a quarter of participants used analgesics or antipyretics for symptom relief. Vaccine efficacy against confirmed COVID-19 held at 95% regardless of medication use, and younger adults, who were the most likely to take pain relievers, showed the same high level of protection as those who did not.² Ibuprofen and acetaminophen are both reasonable choices. The general guidance has been to avoid taking them preemptively before the shot, since the evidence on whether that affects the initial immune response is less clear, but using them to manage symptoms afterward is fine.

For more unusual reactions like prolonged lymph node swelling or menstrual changes, the main recommendation is watchful waiting. If armpit swelling persists beyond a few weeks or causes diagnostic confusion with a scheduled scan, an ultrasound follow-up can confirm the benign nature of the swelling. Menstrual changes that persist beyond two or three cycles warrant a conversation with a healthcare provider to rule out other causes, though vaccination-related disruptions are expected to be self-limiting.

How the Pfizer Vaccine Compares to Others

Among the major COVID vaccines, the Pfizer shot has consistently shown a milder side-effect profile. A cross-sectional study in Saudi Arabia found that the Pfizer vaccine caused significantly fewer side effects than either AstraZeneca or Moderna.²⁸ A large Japanese prospective cohort study confirmed this ordering, with fever and systemic reactions being highest for Moderna, intermediate for AstraZeneca, and lowest for Pfizer.²⁹ The difference between Pfizer and Moderna likely comes down to dose: Moderna’s original formulation contained 100 micrograms of mRNA per shot compared to Pfizer’s 30 micrograms, which is enough to push both immune response and reactogenicity higher.

How Safety Signals Get Caught

The COVID vaccine rollout was one of the most intensively monitored drug deployments in history. In the U.S., multiple overlapping surveillance systems tracked side effects in real time, combining passive systems (where people voluntarily report events) with active systems that follow up with vaccinated individuals proactively. The myocarditis signal illustrated how these layers work together: passive reports flagged an unusual pattern, active surveillance systems confirmed the signal’s reality, and targeted studies then characterized the risk by age and sex.³⁰

The UK ran parallel active monitoring programs that also picked up signals for menstrual disorders and tinnitus. In the case of menstrual changes, the reporting pattern was complicated by media coverage: as news stories about the link spread, more people reported symptoms, making it tricky to separate genuine signal from awareness-driven reporting.¹⁸ This is a recurring challenge in pharmacovigilance: the act of looking for something changes how often you find it. Researchers have proposed finer terminology to distinguish acute vaccination reactions from persistent post-vaccination symptoms that linger for weeks or months, drawing a parallel to the way acute COVID and long COVID are separated.³¹ Whether that distinction gains clinical traction remains to be seen, but it reflects the effort to take persistent complaints seriously while studying them rigorously rather than dismissing them or inflating them.

1
PubMed Central. Common Side Effects of Pfizer COVID-19 Vaccine: An Experience From Pakistan
2
PubMed Central. Ibuprofen, other NSAIDs and COVID-19: a narrative review – Section: Impact of antipyretics and analgesics on the immune response to COVID-19 vaccines
3
Scientific Reports. Impact of sex and age on vaccine-related side effects and their progression after booster mRNA COVID-19 vaccine
4
PubMed Central. Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine
5
JAMA Network Open. Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis
6
PubMed Central. Vaccine hesitancy prospectively predicts nocebo side-effects following COVID-19 vaccination
7
PubMed Central. COVID-19 vaccine induced myocarditis in young males: A systematic review
8
PubMed Central. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex
9
PubMed Central. Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations
10
PubMed Central. Myocarditis After mRNA Vaccination: A Metabolic-Innate Immune Cascade Centered on Lipid Nanoparticles
11
PubMed Central. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine
12
PubMed Central. Axillary Lymphadenopathy after Pfizer-BioNTech and Moderna COVID-19 Vaccination: MRI Evaluation
13
PubMed Central. Ultrasound and shear-wave elastography patterns of COVID-19 mRNA vaccine-related axillary, supra and subclavicular lymphadenopathy
14
PubMed. Time for Resolution of COVID-19 Vaccine-Related Axillary Lymphadenopathy and Associated Factors
15
PubMed Central. Bell’s Palsy and COVID-19 Vaccination: A Systematic Review
16
JAMA Otolaryngology–Head & Neck Surgery. Association of SARS-CoV-2 Vaccination or Infection With Bell Palsy: A Systematic Review and Meta-analysis
17
PubMed Central. Menstrual Changes Following COVID-19 Vaccination: A Cross-Sectional Study
18
PubMed Central. Implementation and Results of Active Vaccine Safety Monitoring During the COVID-19 Pandemic in the UK: A Regulatory Perspective
19
PubMed Central. Safety of BNT162b2 COVID-19 Vaccine in Pregnancy: A Systematic Review
20
PubMed Central. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
21
PubMed Central. Effect of COVID-19 vaccination and booster on maternal–fetal outcomes: a retrospective cohort study
22
PubMed Central. Short-Term Side Effects and SARS-CoV-2 Infection after COVID-19 Pfizer-BioNTech Vaccine in Children Aged 5-11 Years: An Italian Real-World Study
23
PubMed Central. Safety and Immunogenicity of the BNT162b2 COVID-19 Vaccine in Immunocompromised Participants 2 Years and Older: Results of an Open-Label Phase 2b Study
24
PubMed. Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic diseases: A prospective multicenter study
25
PubMed Central. Co-Administration of BNT162b2 COVID-19 and Influenza Vaccines in Adults: A Global Systematic Review
26
JAMA Network Open. Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines: A Randomized Clinical Trial
27
PubMed Central. Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS)
28
PubMed Central. Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study
29
PubMed. Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan
30
PubMed. Overview of U.S. COVID-19 vaccine safety surveillance systems
31
PubMed Central. COVID-19, post-acute COVID-19 syndrome (PACS, “long COVID”) and post-COVID-19 vaccination syndrome (PCVS, “post-COVIDvac-syndrome”): Similarities and differences